The advent of checkpoint inhibitor therapy in medical oncology has led to an increase in hospitalizations for immune-related adverse effects. Severe colitis has been reported in approximately 5% of patients treated with cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) inhibitors, such as ipilimumab. Standard management for those with severe colitis includes administration of systemic corticosteroids with the reservation of antitumor necrosis factor (anti-TNF) therapy, such as infliximab, if there has been no improvement. Rarely, immunotherapy-induced colitis can become life-threatening and result in bowel perforation requiring surgical intervention. Yet, there are no specific recommendations for medical management following colectomy in these situations. In cases of severe colitis from Crohn's disease, postoperative treatment with infliximab has been found to be safe when administered shortly after intestinal resection. However, there remains limited data to support administration of infliximab following bowel perforation due to immunotherapy-induced colitis. Our case illustrates management of a severe adverse reaction to checkpoint inhibitor therapy and the need to further evaluate the role of infliximab postoperatively in patients who develop colitis complicated by bowel perforation.
Conflict of interest statement
The authors declare that there is no conflict of interest regarding the publication of this paper.
Generalized Pyoderma Gangrenosum Associated With Ulcerative Colitis: Successful Treatment With Infliximab and AzathioprineF Chatzinasiou et al. Acta Dermatovenerol Croat 24 (1), 83-5. PMID 27149138. - Case ReportsPyoderma gangrenosum (PG) is a rare ulcerative skin disease, part of the spectrum of neutrophilic and auto-inflammatory dermatoses. Its pathogenesis is unknown, although …
Systematic Review: Colitis Associated With anti-CTLA-4 TherapyA Gupta et al. Aliment Pharmacol Ther 42 (4), 406-17. PMID 26079306. - ReviewGiven the increasing use of anti-CTLA-4 therapy, clinicians must be aware of related adverse events and their management.
Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and ManagementC Prieux-Klotz et al. Target Oncol 12 (3), 301-308. PMID 28540478.Immune checkpoint inhibitors are monoclonal antibodies indicated for an increasing number of malignant diseases. These agents can cause specific side effects, which need …
Infliximab in the Treatment of anti-CTLA4 Antibody (Ipilimumab) Induced Immune-Related ColitisDR Minor et al. Cancer Biother Radiopharm 24 (3), 321-5. PMID 19538054. - Case ReportsThe anti-CTLA4 antibody, ipilimumab, has shown clinical activity against melanoma. Diarrhea due to immune-related colitis is the most frequent serious toxicity and, if un …
TNFα-Inhibitors in Inflammatory Bowel Disease [Internet]T Ringerike et al. PMID 29320135. - ReviewBackground Patients with the inflammatory bowel diseases ulcerative colitis and Crohn’s disease need lifelong treatment and care. Effect of traditional treatme …
Cited by 1 PubMed Central articles
Mesenchymal Stem/Stromal Cells Derived From Dental Tissues: A Comparative In Vitro Evaluation of Their Immunoregulatory Properties Against T CellsMDP De la Rosa-Ruiz et al. Cells 8 (12). PMID 31766697.Bone marrow mesenchymal stem/stromal cells (BM-MSCs) have immunoregulatory properties and have been used as immune regulators for the treatment of graft-versus-host disea …